Video: New SCLC Therapies: DLL3, Tarlatamab, and Antibody-Drug Conjugates Explained

Dr. Neal Ready, medical oncologist at Duke Cancer Institute, shares an in-depth overview of how tumor-associated molecules are shaping the future of small cell lung cancer (SCLC) treatment. This presentation from the SCLC Summit highlights how proteins like DLL3, Trop-2, B7-H3, SEZ6, and GD2 offer new therapeutic targets, and how approaches such as antibody-drug conjugates (ADCs), bispecific antibodies (like Tarlatamab), and CAR T-cell therapies are being developed to improve outcomes for SCLC patients. This session is designed for SCLC patients, care partners, and oncology professionals interested in the science behind next-generation immunotherapy and targeted therapy approaches. Dr. Ready explains how these advances differ from traditional chemotherapy, the role of immune response and treatment durability, and what new options could soon be available through clinical trials and emerging research.

If you have been impacted by lung cancer, we invite you to join us at one of our virtual or in-person meetings. Visit https://www.livelung.org/meetings to learn more and find a meeting near you!

Subscribe to our YouTube channel and click the notification bell so you know when new educational lung cancer videos are available https://www.youtube.com/livelung

his Video Content has been made available for informational and educational purposes only. The Video Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read or seen on the Site.

LiveLung and speakers hereby disclaim any and all liability to any party for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising directly or indirectly from any use of the Video Content, which is provided as is, and without warranties.